Vertex and Genomics enter target pathway collaboration
4 January 2016 | By Victoria White
Vertex Pharmaceuticals is to use Genomic’s integrated database and state-of-the-art analysis tools to identify target therapeutic pathways...
List view / Grid view
News
Drug generates exciting results in metastatic breast cancer models
23 December 2015 | By Victoria White
A team at CSHL has announced preclinical data suggesting the promise of a novel drug directed against a novel target in malignant mammary tumours...
ARA 290 improves islet cell transplantation outcome in Type 1 diabetes
23 December 2015 | By Victoria White
ARA 290 is a first-in-class synthetic peptide designed to activate the innate repair mechanism in the setting of tissue injury...
Study identifies MDSCs as possible prostate cancer target
22 December 2015 | By Victoria White
MDSCs are immune cells that “expand” when faced with cancer, inflammation or infections, giving them the unique ability to suppress the body’s T-cell response to disease...
Enhancing proteasome activity may prevent dementia
22 December 2015 | By Victoria White
A study suggests that enhancing proteasome activity with drugs during the early stages of Alzheimer’s may prevent dementia and reduce damage to the brain...
IMI launches Calls to advance drug development in Ebola, Alzheimer’s and AMD
22 December 2015 | By Victoria White
The IMI has launched two Calls for proposals that will advance drug development in Ebola, childhood cancers, neurological disorders, and eye disease...
Mimetas awarded funding for organ-on-a-chip neurotoxicity models
22 December 2015 | By Victoria White
The funding is awarded in the context of the Neuratect CRACK IT Challenge to support development of better predictive, high-throughput, animal-free models for neurotoxicity of medicines and chemicals...
Bayer and CRISPR Therapeutics join forces for breakthrough therapies
21 December 2015 | By Victoria White
Bayer and CRISPR Therapeutics are to form the joint venture to discover, develop and commercialise new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease...
Janssen and Bavarian Nordic team up for HPV infection vaccine
21 December 2015 | By Victoria White
Their goal is to develop a therapeutic vaccine which aims to intercept HPV infection-related disease, particularly in those who are diagnosed with HPV early, by enhancing the ability of the immune system to treat chronic infections and prevent progression to cancer...
Variant and L&F Research to advance development of VAR 200
18 December 2015 | By Victoria White
Variant says VAR 200 has potential for treating multiple indications associated with the damaging effects of cellular accumulation of cholesterol and lipids on the kidney, including focal segmental glomerulosclerosis...
Ligand Pharmaceuticals to acquire OMT for $178 million
18 December 2015 | By Victoria White
OMT has leading antibody drug discovery technology and is believed to be the only company in the world offering three transgenic animal platforms for license...
Duel homing agent could aid brain injury recovery
17 December 2015 | By Victoria White
When given to mice, the new ‘homing’ agent inactivated the complement system in the brain, reduced inflammation and aided recovery...
ReNeuron holds inaugral meeting of its new Scientific Advisory Board
17 December 2015 | By Victoria White
The Scientific Advisory Board comprises nine leading academics and industry executives with a world-class breadth of expertise across the Company’s areas of operation...
Immunocore expands management team; opens US office
17 December 2015 | By Victoria White
The new premises will accommodate the Company’s US clinical development, medical and regulatory operations and provide an important base for Immunocore’s ongoing US activities...
New £3.4 million project to investigate protein-protein interactions
15 December 2015 | By Victoria White
There are thought to be as many as 600,000 protein-protein interactions that could be targets for new drugs. The project seeks to analyse and categorise the important features of these interactions...